Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, Annabelle Godet, Katalin Pungor & Srihari Gopal. (2021) Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient Preference and Adherence 15, pages 2239-2248.
Read now
Read now
Fabio Magliocco, Renato de Filippis, Matteo Aloi, Filippo Antonio Staltari, Raffaele Gaetano, Cristina Segura-Garcia & Pasquale De Fazio. (2020) Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study. International Journal of Psychiatry in Clinical Practice 24:2, pages 201-207.
Read now
Read now
Articles from other publishers (14)
Shin-Tian Chien, Ian T. Suydam & Kim A. Woodrow. (2023) Prodrug approaches for the development of a long-acting drug delivery systems. Advanced Drug Delivery Reviews 198, pages 114860.
Crossref
Crossref
Chun Ting Chan, Swapna Verma, Mythily Subramaniam, Edimansyah Abdin & Jenny Tay. (2023) Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis—A Retrospective Mirror-Image Study. International Journal of Environmental Research and Public Health 20:4, pages 3403.
Crossref
Crossref
Young-Chul Chung, Yen Kuang Yang, Ahmad Hatim Sulaiman, Paul Bergmans & Wilson Tan. (2022) Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting. Clinical Psychopharmacology and Neuroscience 20:3, pages 427-439.
Crossref
Crossref
Dandan Wang, Ning Wei, Fangzhen Hu, Jianhua Li, Yucheng Wang, Zhiwei Qian, Miao Yang, Mingrong Yao, Yong Xia, Hong Yu, Wenzhen Tu, Minjie Ye, Cheng Qian, Jianbo Hu, Jingkai Chen, Chanchan Hu, Manli Huang, Yi Xu & Shaohua Hu. (2022) Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology 42:4, pages 383-390.
Crossref
Crossref
George T. Kannarkat, Stanley N. Caroff & James F. Morley. (2022) Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. Tremor and Other Hyperkinetic Movements 12:1.
Crossref
Crossref
Vjekoslav Peitl, Branka Aukst Margetić, Branka Vidrih & Dalibor Karlović. (2022) The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting. Clinical Psychopharmacology and Neuroscience 20:1, pages 118-125.
Crossref
Crossref
Minze Zhu, Andrew K. Whittaker, Felicity Y. Han & Maree T. Smith. (2022) Journey to the Market: The Evolution of Biodegradable Drug Delivery Systems. Applied Sciences 12:2, pages 935.
Crossref
Crossref
L.A. Burygina, S.A. Golubev, A.Yu. Berezantsev & E.A. Shumakova. (2022) Transfer from paliperidone of one-month action to paliperidone of three-month action in schizophrenia spectrum disorders: clinical aspects, pharmacological strategies, therapeutic prediction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:1, pages 13.
Crossref
Crossref
Sheldon H. Preskorn. (2022) How Loading Dose Strategies for Depot Paliperidone Can Go Wrong. Journal of Psychiatric Practice 28:2, pages 130-137.
Crossref
Crossref
Marit Tveito, Gudrun Høiseth, Tore Haslemo, Espen Molden & Robert Løvsletten Smith. (2021) Impact of age and gender on paliperidone exposure in patients after administration of long-acting injectable formulations—an observational study using blood samples from 1223 patients. European Journal of Clinical Pharmacology 77:8, pages 1201-1208.
Crossref
Crossref
Charmi Patel, Bruno Emond, Marie-Hélène Lafeuille, Aurélie Côté-Sergent, Patrick Lefebvre, Neeta Tandon & Antoine C. El Khoury. (2019) Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. Drugs - Real World Outcomes 7:1, pages 19-29.
Crossref
Crossref
Sanjoy Das, Malay K. Das, Trinayan Deka, L. Ronibala Singha & Punamjyoti Das. 2020. Nano Medicine and Nano Safety. Nano Medicine and Nano Safety
99
141
.
Angela Abruzzo, Teresa Cerchiara, Barbara Luppi & Federica Bigucci. (2019) Transdermal Delivery of Antipsychotics: Rationale and Current Status. CNS Drugs 33:9, pages 849-865.
Crossref
Crossref
Maral DerSarkissian, Patrick Lefebvre, Kruti Joshi, Brianne Brown, Marie-Hélène Lafeuille, Rachel H. Bhak, Michael Hellstern, Priyanka Bobbili, Brian Shiner, Antoine C. El Khoury & Yinong Young-Xu. (2018) Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. Clinical Therapeutics 40:9, pages 1496-1508.
Crossref
Crossref